Neurocrine Biosciences | NBIX - Debt



Neurocrine Biosciences reported $439.1M in Debt for its fiscal quarter ending in June of 2025.


Debt Change Date
AbbVie USD 69.89B 2.74B Mar/2025
Acadia Pharmaceuticals USD 56.29M 56.29M Jun/2025
Agios Pharmaceuticals USD 48.76M 48.76M Jun/2025
ALKERMES USD 72.68M 72.68M Jun/2025
Alnylam Pharmaceuticals USD 1.3B 271.5M Jun/2025
Amgen USD 56.2B 1.18B Jun/2025
Biogen USD 6.59B 296.8M Jun/2025
BioMarin Pharmaceutical USD 603.87M 8.22M Jun/2025
Cytokinetics USD 658.13M 1.01M Mar/2025
Dynavax Technologies USD 260.51M 36.65M Mar/2025
Exelixis USD 179.84M 179.84M Jun/2025
Gilead Sciences USD 24.95B 6M Jun/2025
Halozyme Therapeutics USD 1.51B 1.65M Jun/2025
Incyte USD 42.41M 5.29M Jun/2025
Ionis Pharmaceuticals USD 1.42B 169.27M Jun/2025
Neurocrine Biosciences USD 439.1M 8.4M Jun/2025
Pfizer USD 60.93B 1.18B Jun/2025
Prothena USD 9.78M 9.78M Jun/2025
Regeneron Pharmaceuticals USD 2.71B 300K Jun/2025
Repligen USD 533.72M 149.97M Jun/2025
Sarepta Therapeutics USD 1.35B 215.59M Jun/2025
Teva Pharmaceutical Industries USD 17.52B 872M Jun/2025
Ultragenyx Pharmaceutical USD 36.3M 1.98M Jun/2025
Vertex Pharmaceuticals USD 1.53B 121.7M Jun/2025